Jefferies Maintains Buy on PAREXEL Int'l (PRXL)

Jefferies is out with its report today on PAREXEL Int'l PRXL, maintaining Buy. In a note to clients, Jefferies writes, "PAREXEL reported earnings that missed expectations. Management's guidance reduces revenue, but offsets that with higher costs? Share gains continue to drive high backlog growth. Completion of systems implementations and LEAP initiative promise cost savings, but near-term stumbles challenge investors long-term patience." Piper Jaffray has a $30 PT on PRXL. Shares of PRXL closed Monday at $27.02, down 2.67% from Friday's close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsHealth CareJefferiesLife Sciences Tools & ServicesPAREXEL Int'l
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!